Health & Fitness
Health and Fitness
Health and Fitness
Wed, May 26, 2010 Viral Genetics Appoints Dr. Baruch S. Blumberg to its Advisory Board
SAN MARINO, Calif.--([ BUSINESS WIRE ])--Nobel Laureate Dr. Baruch S. Blumberg, MD, PhD., has joined the advisory board of Viral Genetics, Inc., (OTC:VRAL.PK) headquartered in San Marino, California. Dr. Blumberg won the 1976 Nobel Prize in Medicine for the discovery of the Hepatitis-B virus. He is the second Nobel Laureate to join the advisory board of Viral Genetics, a biotechnology company pursing drug compounds for people with autoimmune diseases including HIV/AIDS and Lyme Disease, as well as investigating treatments for staph, strep and drug resistant cancer cells. Dr. Blumberg developed the diagnostic test for the detection of the Hepatitis-B virus and the first retroviral vaccine for protection from its dreaded consequences. He is credited with saving many millions of lives.
"We look forward to his guidance in helping our drug therapies reach their full potential."
aIa™m very impressed by the results of Viral Geneticsa™ laboratory testing on its drug compounds,a said Dr. Blumberg. aThis company offers hope for patients with a wide range of diagnoses.a
Dr. Blumberg will join fellow board members that include 2008 Nobel Prize recipient in medicine, Dr. Luc Montagnier, the co-discoverer of the HIV virus, and former U.S. Surgeon General Dr. C. Everett Koop. His role will be to assist Viral Genetics with bringing its drug compounds from the laboratory to the clinical trial phase.
aDr. Blumberga™s belief in our research is extremely exciting,a said Viral Genetics CEO Haig Keledjian. aWe look forward to his guidance in helping our drug therapies reach their full potential.a
The advisory board also includes Dr. Eric Rosenberg, associate professor of the Harvard Medical School; Dr. Leslie Benet, a drug development expert, Marshall C. Phelps, head of intellectual property for Microsoft Corporation; Richard T. Gerstner, a former senior corporate executive for IBM and Telular Corporation; and Anthony Freda, Jr., a senior executive with global business management experience.
Dr. Blumberg will contribute a rich resume and extensive, invaluable experience to the Viral Genetics advisory board. He obtained his undergraduate degree in Physics from Union College in Schnectedy, New York, entered graduate school at Columbia University, and then the College of Physicians and Surgeons at where he earned his Doctorate in Medicine. He then won a fellowship to Balliol College, Oxford University, in 1955, and was awarded a Ph.D. in biochemistry. Dr. Blumberg returned to Oxford as Master of Balliol College, becoming the first American and scientist to have ever been awarded this prestigious chair.
Dr Blumberg at various times was a researcher at the NIH, founding director ofthe NASA Astrobiology Institute (NAI), a Senior Advisor for Biology to the Administrator of NASA in Washington, DC. and a professor of medicine and anthropology at the University of Pennsylvania; He later became vice president of population oncology at the famed Fox Chase Institute of Cancer Research in Philadelphia where he now resides.
ABOUT VIRAL GENETICS
Headquartered in San Marino, California, Viral Genetics discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its targeted peptide technology (TPT), metabolic disruption technology (MDT) and thymus nuclear protein compound (TNP). Viral Genetics has optioned the exclusive right to develop any and all drug therapies based on TPT and MDT technology through an agreement with the University of Colorado. Viral Genetics alsohas an Exclusive License Agreement with the University of Colorado to license technology that appears to explain TNP and may result in additional drug therapies. Viral Genetics has formed a wholly owned subsidiary, MetaCytoLytics, Inc, to advance its research into MDT. Online at [ www.viralgenetics.com ].
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with Pink Sheets. None of Viral Geneticsa™ drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained herein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies, including VGV-X, VGV-L, and VGV-S, in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
